Consistent with miR-125b’s leukemogenic function, co-transducing 5-FU-treated BM cells with miR-125b (overexpressed 500-fold) and the BCR-ABL fusion gene or mutant C/EBPα accelerated the development of leukemia (B-ALL, MPN, or mixed leukemia with BCR-ABL, and myeloid leukemia with C/EBPα; Bousquet et al., 2010; Enomoto et al., 2012). The gene discussed is CEBPA; the disease is myeloid leukemia.